Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Trials|December 31, 2024
Health checks for autistic adults: study protocol for a cluster randomised controlled trialJeremy R Parr, Helen Taylor, Colin Wilson, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
BMC Medicine|October 2, 2025
Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trialsHelen Mossop, Zoë Walmsley, Nina Wilson, et al.
BMC Medicine|October 26, 2021
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials projectNina Wilson, Katie Biggs, Sarah Bowden, et al.
The Lancet. Rheumatology|May 24, 2025
Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort studyAdam Al-Hakim, Roochi Trikha, Ei Ei Phyu Htut, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|December 19, 2003
Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset ADAmanda J Myers, Helen Marshall, Peter Holmans, et al.
American Heart Journal|August 10, 2018
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trialOmar Mukhtar, Joseph Cheriyan, John R Cockcroft, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
Pulmonary Circulation|March 19, 2024
Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologiesFrances Varian, Jennifer Dick, Christian Battersby, et al.
Pageof 19